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Objectives The purpose of this study was to investigate whether liposomal adenosine has stronger cardioprotective effects
and fewer side effects than free adenosine.
Background Liposomes are nanoparticles that can deliver various agents to target tissues and delay degradation of these agents.
Liposomes coated with polyethylene glycol (PEG) prolong the residence time of drugs in the blood. Although adeno-
sine reduces the myocardial infarct (MI) size in clinical trials, it also causes hypotension and bradycardia.
Methods We prepared PEGylated liposomal adenosine (mean diameter 134  21 nm) by the hydration method. In rats,
we evaluated the myocardial accumulation of liposomes and MI size at 3 h after 30 min of ischemia followed by
reperfusion.
Results The electron microscopy and ex vivo bioluminescence imaging showed the specific accumulation of liposomes in
ischemic/reperfused myocardium. Investigation of radioisotope-labeled adenosine encapsulated in PEGylated
liposomes revealed a prolonged blood residence time. An intravenous infusion of PEGylated liposomal adeno-
sine (450 g/kg/min) had a weaker effect on blood pressure and heart rate than the corresponding dose of free
adenosine. An intravenous infusion of PEGylated liposomal adenosine (450 g/kg/min) for 10 min from 5 min
before the onset of reperfusion significantly reduced MI size (29.5  6.5%) compared with an infusion of saline
(53.2  3.5%, p  0.05). The antagonist of adenosine A1, A2a, A2b, or A3 subtype receptor blocked cardioprotec-
tion observed in the PEGylated liposomal adenosine-treated group.
Conclusions An infusion as PEGylated liposomes augmented the cardioprotective effects of adenosine against ischemia/
reperfusion injury and reduced its unfavorable hemodynamic effects. Liposomes are promising for developing
new treatments for acute MI. (J Am Coll Cardiol 2009;53:709–17) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.014c
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wiposomes are now widely used for drug delivery in cancer
reatment to target specific organs actively or passively and
o prevent the degradation of chemotherapy agents (1).
owever, the application of liposomes for cardiovascular
iseases is still limited. In ischemic/reperfused myocardium,
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Drug Delivery System Targeting Injured Myocardium February 24, 2009:709–17such as liposomes may be a prom-
ising drug delivery system for tar-
geting damaged myocardium with
cardioprotective agents. Addition-
ally, coating liposomes with poly-
ethylene glycol (PEG) prolongs
their residence time in the circula-
tion (1). Because enhanced micro-
vascular permeability persists for at
least 48 h after the occurrence of
myocardial infarction (MI) (2),
drugs delivered in PEGylated li-
osomes should be able to display their maximum beneficial
ffects on myocardial damage after MI.
Adenosine has multiple physiological functions that are
ediated via the adenosine A1, A2a, A2b, and A3 receptors
4,5). Although large-scale clinical trials suggested the
otential value of adenosine therapy for patients with acute
I (6,7), this agent has an extremely short half-life (1 to
s) and causes hypotension and bradycardia because of
asodilatory and negative chronotropic effects (4). Because a
igh dose of adenosine is required to exert cardioprotective
ffects, it is difficult to use clinically because of the associated
emodynamic consequences. Therefore, we hypothesized
hat adenosine encapsulated in PEGylated liposomes would
ause less hemodynamic disturbance and might also specif-
cally accumulate in ischemic/reperfused myocardium, lead-
ng to augmented cardioprotective effects. To test this
ypothesis, we created PEGylated liposomal adenosine by
he hydration method and investigated: 1) whether liposo-
al adenosine accumulated in ischemic/reperfused myocar-
ium and prolonged blood residence time; 2) whether
iposomal adenosine caused less severe hypotension and
radycardia than free adenosine; and 3) which adenosine
eceptor subtype was involved in mediating the cardiopro-
ective effects of liposomal adenosine against ischemia/
eperfusion injury.
ethods
aterials. The materials for preparing PEGylated lipo-
omes, including hydrogenated soy phosphatidyl choline
HSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
-[methoxy (polyethylene glycol)-2000] (DSPE-PEG2000),
nd cholesterol were obtained from Nissei Oil Co., Ltd.
Tokyo, Japan) and Wako Pure Chemical Co., Ltd. (Osaka,
apan). [3H]-adenosine was purchased from Daiichi Pure
hemicals Co., Ltd. (Tokyo, Japan). Other materials were
btained from Sigma (St. Louis, Missouri), including 8-(p-
ulfophenyl)theophylline (8-SPT; a nonselective adenosine
eceptor antagonist), 1,3-diethyl-8-phenylxanthine (DPCPX;
selective adenosine A1 receptor antagonist), 5-amino-7-
phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]
yrimidine (SCH58261; a selective adenosine A2a receptor
ntagonist), 8-[4-[((4-cyanophenyl)carbamoylmethyl)
Abbreviations
and Acronyms
8-SPT  8-(p-sulfophenyl)
theophylline
EM  electron microscopy
MI  myocardial infarction
PEG  polyethylene glycol
RI  radioisotope
TTC  triphenyltetrazolium
chloridexy]phenyl]-1, 3-di(n-propyl)xanthine (MRS1754; a selective denosine A2b receptor antagonist), and 5-propyl-2-ethyl-
-propyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-
-carboxylate (MRS1523, a selective adenosine A3 receptor
ntagonist).
nimals. Male Wistar rats (9 weeks old and weighing 250
o 310 g, Japan Animals, Osaka, Japan) were used. The
nimal experiments were approved by the National Cardio-
ascular Center Research Committee and were performed
ccording to institutional guidelines.
reparation of PEGylated liposomes. The PEGylated
iposomes were prepared by the hydration method. Briefly,
denosine was added to the lipid solution. After mixture of
ipid and adenosine, DSPE-PEG2000 was added and incu-
ated. The final composition of PEGylated liposomes was
SPC:cholesterol:DSPE-PEG2000  6.0:4.0:0.3 (molar
atio). After ultracentrifugation several times, the pellet of
iposomal adenosine was resuspended in sodium lactate at
ach required concentration for use in the experimental
rotocols. Some samples of final liposomal adenosine were
isrupted by dilution with 50% methanol (1.5 ml per 30-l
f liposomes). After 10 min of ultracentrifugation, the
oncentration of adenosine in the supernatant was measured
y high-performance liquid chromatography.
To prepare fluorescent-labeled liposomes, 0.5 mol% tet-
amethylrhodamine isothiocyanate (rhodamine) was added
o the lipid mixture. To prepare radioisotope (RI)-labeled
denosine encapsulated in liposomes, [3H]-radiolabeled
denosine (Daiichi Pure Chemicals, Tokyo, Japan) was
iluted with free adenosine and was encapsulated in lipo-
omes as described above.
haracterization of PEGylated liposomal adenosine. The
haracterization of the liposomes was performed by the
ynamic scatter analysis (Zetasizer Nano ZS, Malvern,
orcestershire, United Kingdom). The analyses were per-
ormed 10 times per sample, and results represented analy-
es of 4 independent experiments.
xperimental protocols. PROTOCOL 1: EFFECTS OF PEGY-
ATED LIPOSOMAL ADENOSINE ON HEMODYNAMICS IN
ATS. Rats were anesthetized with intraperitoneal sodium
entobarbital (50 mg/kg). Catheters were advanced into a
emoral artery and vein for the measurement of systemic
lood pressure and infusion of drugs, respectively. Both
lood pressure and heart rate were monitored continuously
uring the study using a Power Lab (AD Instruments,
astle Hill, Australia). After hemodynamics became stable,
e intravenously administered empty PEGylated liposomes
n  8), free adenosine (n  8), or PEGylated liposomal
denosine (n  8) for 10 min. Either PEGylated lipo-
omal or free adenosine was infused at an initial dose of
25 g/kg/min (0.1 ml/min) for 10 min. After a 5-min
nterval, either PEGylated liposomal adenosine or free
denosine was infused at 450 g/kg/min (0.1 ml/min) for
0 min. In the same manner, PEGylated liposomal
denosine or free adenosine was then infused at 900
g/kg/min (0.1 ml/min).
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February 24, 2009:709–17 Drug Delivery System Targeting Injured MyocardiumROTOCOL 2: EFFECTS OF PEGYLATED LIPOSOMAL ADENOSINE
N INFARCT SIZE IN RATS. The MI was induced by transient
igation of the left coronary artery as described previously
8). In the first series of experiments, to examine the
ose-dependent effects of liposomal adenosine on MI size,
EGylated liposomal adenosine was infused intravenously
t 50, 150, or 450 g/kg/min for a 10-min period starting
rom 5 min before the onset of reperfusion. In the second
eries of experiments, to determine the adenosine receptor
ubtype involved in cardioprotective effects by the liposomal
denosine, the antagonist of adenosine subtype receptor was
ntravenously injected as a bolus followed by the infusion of
iposomal adenosine for 10 min. The MI size was evaluated
t 3 h after the start of reperfusion. The doses of adenosine
eceptor subtype antagonists were determined according to
he previous reports (9–11).
easurement of infarct size. At 3 h after the onset of
eperfusion, the area at risk and the infarcted area were
etermined by Evans blue and triphenyltetrazolium chloride
TTC) staining, respectively, as previously described (8).
nfarct size was calculated as [infarcted area/area at risk] 
00(%) in a blind manner. The area at risk was composed of
order (TTC staining) and infarcted (TTC nonstaining)
reas.
lectron microscopy (EM). Myocardial samples for EM
ere obtained from the central and peripheral areas in
schemic/reperfused myocardium, which roughly corre-
ponded to the infarcted and border areas, respectively, after
he left coronary artery was occluded for 30 min of ischemia
ollowed by 3 h of reperfusion. Samples were prepared as
reviously reported (12). Liposomes, whose major mem-
rane component is unsaturated phospholipids, were visu-
lized as homogenous dark dots with a diameter of 100 to
50 nm (13).
ccumulation of fluorescent-labeled PEGylated lipo-
omes in ischemic/reperfused myocardium. Unlabeled or
uorescent-labeled PEGylated liposomes were infused in-
ravenously at a dose of 0.1 ml/min as liposomal adenosine
as infused in protocol 2. At 3 h after reperfusion, hearts
ere quickly removed and cut into 4 sections parallel to the
xis from base to apex. Then ex vivo bioluminescence
maging was performed with an Olympus OV 100 imaging
ystem (Olympus, Tokyo, Japan) and signals were quanti-
ed using WASABI quantitative software (Hamamatsu
hotonics K.K., Shizuoka, Japan). Fluorescent intensity in
he region of interest was measured as previously reported
14). Control intensity indicated the fluorescent intensity in
he nonischemic area of the individual rat.
Characterization of Liposomes by Dynamic Light
Table 1 Characterization of Liposomes by D
Mean Diame
PEGylated liposomes (empty liposomes) 126
PEGylated liposomal adenosine 134Results represented analysis of 4 independent experiments. Values are expre
PEG  polyethylene glycol.ime-course changes of free and PEGylated liposomal
I-labeled adenosine in plasma and myocardium. Free
r PEGylated liposomal [3H]-adenosine (83 kBq per rat) was
nfused intravenously at a dose of 0.1 ml/min as liposomal
denosine was infused in protocol 2. At the time indicated, rat
earts were harvested for counting of radioactivity (LSC-3100,
loka Co., Tokyo, Japan). Results are expressed as a percent-
ge of the injected dose per 1 ml of blood or 1 g of wet tissue
eight.
tatistical analysis. The parameters of the liposomes were
xpressed as the average  SD, whereas other data were
xpressed as the average  SEM. Comparison of time-
ourse changes in hemodynamic parameters between groups
as performed by 2-way repeated-measures analysis of
ariance (ANOVA) followed by a post-hoc Bonferroni test.
or comparison of RI activity between groups, statistical
nalysis was done with the Mann-Whitney U test. To
ddress the differences in infarct size among groups, we
erformed a nonparametric (Kruskal-Wallis) test followed
y evaluation with the Mann-Whitney U test. Resulting p
alues were corrected according to the Bonferroni method.
o compare parameters of liposomes, an unpaired t test was
erformed. In all analyses, p  0.05 was considered to
ndicate statistical significance.
esults
haracterization of liposomes by dynamic light scatter
nalysis. The dynamic light scatter analysis showed no sig-
ificant difference in mean diameter, polydispersity index, or
eta-potential distribution between empty and adenosine-
oaded PEGylated liposomes (Table 1).
iposomes in ischemic/reperfused myocardium. The
M revealed the intact vascular endothelial cells and cardio-
yocytes in the nonischemic myocardium (Figs. 1A and 1B).
here were no homogenous dark dots indicating liposomes
n the nonischemic myocardium of rats that received either
aline (Fig. 1A) or liposomes (Fig. 1B). In the border area,
any homogenous dark dots indicating liposomes were
ccumulated in rats that received liposomes, but not saline
Figs. 1C and 1D). In this area, significant structural
amage was not observed in endothelium, but slight swell-
ng of mitochondria was often observed. In the infarcted
rea, numerous liposomes were detected in rats that received
iposomes, but not saline (Figs. 1E and 1F). In this area, the
isrupted endothelial integrity and marked swelling of
itochondria were often observed.
tter Analysis
ic Light Scatter Analysis
m) Polydispersity Index Zeta Potential (mV)
0.035 0.003 1.7 0.4
0.094 0.002 2.3 1.1Sca
ynam
ter (n
12
21ssed as mean  SD.
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Drug Delivery System Targeting Injured Myocardium February 24, 2009:709–17luorescent-labeled PEGylated liposomes in ischemic/
eperfused myocardium. Quantitative analysis by biolumi-
escence ex vivo bioluminescene imaging revealed that the
arget to control fluorescent intensity ratio was higher in
he border (noninfarcted area at risk) as well as infarcted
reas compared with a nonischemic one, suggesting that
uorescent-labeled liposomes were accumulated in the bor-
er as well as infarcted areas. Since there was no high-
ntensity area when unlabeled liposomes were infused, it was
uggested that this was not a nonspecific phenomenon to
I by the ex vivo bioluminescence imaging system (Fig. 2).
he Evans blue staining was unrelated to the fluorescence
Saline
 
Non-ischemic
area

Border
area
Necrotic 
area

Figure 1 Liposomes in Ischemic/Reperfused Myocardium
(A, B) Representative electron micrographs of the nonischemic area in rats that re
border area at 3 h after myocardial infarction (MI). Many dark dots accumulated in
tron micrographs of infarcted areas at 3 h after MI. Numerous dark dots accumula
1 m.ntensity (data not shown). tPlasma radioactivity of RI-labeled adenosine was mark-
dly higher in the PEGylated liposomal adenosine group at
0 min and 3 h after the intravenous infusion than in the
ree adenosine group (Fig. 3A). Encapsulation within
EGylated liposomes also augmented the accumulation of
denosine in ischemic/reperfused myocardium compared
ith that of free adenosine (Fig. 3B).
emodynamic effects of PEGylated liposomal adeno-
ine. Baseline hemodynamic parameters did not differ
mong the groups. An intravenous infusion of free adeno-
ine at doses of 225, 450, and 900 g/kg/min decreased the
ean blood pressure by 14.8%, 25.4%, and 33.7%, respec-
Liposomes


Lp

Lp
saline (A) or liposomes (Lp) (B). (C, D) Representative electron micrographs of
rea in the rat that received liposomes but not saline. (E, F) Representative elec-
this area in the rat that received liposomes but not saline. Scale bars representceived
this a
ted inively, compared with the effect of empty PEGylated lipo-
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February 24, 2009:709–17 Drug Delivery System Targeting Injured Myocardiumomes. In contrast, the intravenous infusion of PEGylated
iposomal adenosine at a dose of either 225 or 450 g/kg/
in did not significantly alter mean blood pressure (Fig. 4).
hanges of the heart rate after infusion of PEGylated
iposomal adenosine or free adenosine were similar to those
bserved for mean blood pressure (Fig. 4).
ffects of PEGylated liposomal adenosine on MI size.
aseline hemodynamic parameters were similar among all of
he groups (Table 2). Intravenous infusion of free adenosine for
0 min reduced both the blood pressure and the heart rate,
lthough these parameters returned to baseline within 5 min of
easing infusion (Table 2). In contrast, hemodynamic param-
ters of the other groups were not altered (Table 2). The area
t risk in the control group (61  3%) did not differ
ompared with those of other groups that received liposo-
al adenosine. Intravenous infusion of PEGylated liposo-
8
6
4
2
0
Non-fluorescent  Lp
Border area Necrotic areaNon-ischemic
area
A
Figure 2 Detection of Fluorescence-Labeled PEGylated Liposom
Quantitative analysis of target-to-control fluorescent intensity ratio for each area in
somes. The values of bioluminescence signals in the border and infarcted areas w
as the mean  SEM (error bars). *p  0.05 versus nonischemic areas. #p  0.0
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Figure 3 Radioisotope-Labeled Adenosine in Plasma and Ischem
(A) Changes in plasma radioactivity after infusion of radioisotope-labeled adenosin
sine groups, respectively (n  4 each). In the PEGylated liposomal adenosine grou
(B) Changes in radioactivity in ischemic/reperfused myocardium. Solid and open b
tively (n  4 each). In the PEGylated liposomal adenosine group, myocardial radio
the mean  SEM (error bars). *p  0.05 versus the free adenosine group at theal adenosine caused a dose-dependent decrease of MI size
ompared with that in the control group, whereas intrave-
ous infusion of empty PEGylated liposomes or free aden-
sine did not (Fig. 5B).
The bolus injection of adenosine receptor antagonist did
ot alter the hemodynamic parameters (Table 3). The area
t risk in the liposomal adenosine group (58  3%) did not
iffer compared with those of other groups that received
denosine receptor antagonist. Infusion of 8-SPT, a non-
pecific adenosine receptor antagonist, blunted the cardio-
rotective effect of liposomal adenosine (Fig. 6B). Further-
ore, the infusion of the adenosine A1, A2a, A2b, or A3
eceptor antagonist also blunted cardioprotective effects of
iposomal adenosine (Fig. 6B). Infusion of 8-SPT alone did
ot significantly affect myocardial infarct size compared
ith the control (52  5%, n  4).
8
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Fluorescent  Lp
* #
*
Border area Necrotic areaNon-ischemic
area
Ischemic/Reperfused Myocardium
n  3 each group) that received nonfluorescent (A) or fluorescent (B) lipo-
pressed as the fold to that of the each nonischemic area. Values are expressed
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id and open bars indicate the PEGylated liposomal adenosine and free adeno-
sma radioactivity was markedly higher than in the free adenosine group.
dicate the PEGylated liposomal adenosine and free adenosine groups, respec-
was markedly higher than in the free adenosine group. Values are expressed as
ponding time.B
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n the present study, EM, bioluminescence ex vivo imaging,
nd fluorescent analysis revealed the accumulation of liposomes
n the border (noninfarcted areas at risk) as well as infarcted
nes, but not nonischemic myocardium, at 3 h after MI. These
ndings suggested that liposomes could specifically accumulate
n ischemic/reperfused myocardium. Interestingly, EM re-
ealed the existence of liposomes at sites where endothelial
ntegrity was still morphologically maintained. Endothelial
ysfunction such as enhanced permeability is induced by
schemic insult without morphological endothelial disruption
3,15). Enhanced permeability might lead to the accumulation
f liposomes in the border as well as infarcted area, which will
Figure 4 Hemodynamic Effects of PEGylated Liposomal Adenos
Changes in the mean blood pressure (A) and heart rate (B) after intravenous infu
adenosine (circles), or free adenosine (squares) (n  8 each). Values are expres
#p  0.05 versus PEGylated liposomes.
ffects of Liposomal Adenosine on Hemodynamic Parameters
Table 2 Effects of Liposomal Adenosine on Hemodynamic Para
Baseline 0 min 1
Mean blood pressure (mm Hg)
Saline 122 5 102 10 10
Vehicle 127 4 109 8 10
Free-Ado 124 8 115 8 11
Lp-Ado 50 g/kg/min 121 5 106 6 10
Lp-Ado 150 g/kg/min 122 3 107 6 10
Lp-Ado 450 g/kg/min 124 3 104 6 10
Heart rate (beats/min)
Saline 363 22 366 19 36
Vehicle 363 32 363 6 38
Free-Ado 360 18 361 17 38
Lp-Ado 50 g/kg/min 378 19 386 21 36
Lp-Ado 150 g/kg/min 388 27 376 20 37
Lp-Ado 450 g/kg/min 368 17 376 21 36alues are expressed as mean  SEM. *p  0.05 versus baseline.
Free-Ado  free adenosine; Lp-Ado  PEGylated liposomal adenosine; PEG  polyethylene glycol; vehontribute to salvage the ischemic/reperfused myocardium.
owever, further investigation will be needed to determine the
recise mechanism by which liposomes accumulate in isch-
mic/reperfused myocardium.
Analysis using RI-labeled adenosine encapsulated in
iposomes revealed that plasma radioactivity was markedly
igher in the PEGylated liposomal adenosine group com-
ared with the free adenosine group. This indicates that
ncapsulation of adenosine by PEGylated liposomes con-
iderably prolonged its residence time in the circulation and
elayed its degradation. Consistent with the histological
ata, RI-labeled adenosine also showed preferential accu-
ulation in ischemic/reperfused myocardium.
f various doses of empty PEGylated liposomes (triangles), PEGylated liposomal
the mean  SEM. *p  0.05 versus baseline at the corresponding group.
rs
Ischemia Reperfusion
25 min 30 min 5 min 10 min
107 9 108 7 105 9 104 9
111 9 111 5 105 5 103 5
109 4 66 4* 62 4* 112 6
110 10 102 6 101 6 104 4
109 11 105 6 100 6 103 4
107 5 102 6 99 6 104 4
4 413 22 372 12 372 16 371 14
396 25 367 6 374 7 372 7
3 379 18 305 11* 293 13* 356 14
2 376 12 367 19 369 9 377 17
4 377 13 378 16 373 16 369 17
3 386 15 368 15 363 6 367 7ine
sion o
sed asmete
5 min
8 7
8 7
1 5
5 6
7 6
5 6
9 1
3 6
4 1
6 1
1 1
1 1icle  PEGylated liposomes.
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February 24, 2009:709–17 Drug Delivery System Targeting Injured MyocardiumFurthermore, this study showed that PEGylated liposomal
denosine had a weaker effect on the blood pressure and heart
ate than free adenosine. Thus, encapsulating adenosine in
EGylated liposomes attenuated its vasodilatory and negative
hronotropic effects, presumably by reducing the amount of
irculating free adenosine. However, the changes of hemo-
ynamic parameters in this in vivo model suggested that
ignificant release of adenosine from PEGylated liposomes
ould still occur if a large dose of liposomal adenosine (e.g.,
00 g/kg/min) were administered. Thus, further investi-
180 min Repe30 min Occlusion
0 25 35
Drug infusion
Measur
A
B
0
10
20
30
40
50
60
70
80
90
(%)
Figure 5 Dose-Dependent Effects of PEGylated Liposomal Aden
(A) Protocol showing the timing of infusion of PEGylated liposomal adenosine and
mean  SEM (error bars). *p  0.05 versus the control group. Free-Ado  free adeno
ffects of Adenosine Receptor Antagonist on Hemodynamic Param
Table 3 Effects of Adenosine Receptor Antagonist on Hemodyn
Baseline 0 min 1
Mean blood pressure (mm Hg)
Lp-Ado  8SPT 120 6 113 4 11
Lp-Ado  DPCPX 130 6 105 4 12
Lp-Ado  SCH58261 132 2 98 12 9
Lp-Ado  MRS1754 130 3 95 12 10
Lp-Ado  MRS1523 130 2 109 8 10
Heart rate (beats/min)
Lp-Ado  8SPT 404 17 385 10 37
Lp-Ado  DPCPX 396 24 380 11 39
Lp-Ado  SCH58261 393 14 399 15 38
Lp-Ado  MRS1754 398 14 392 11 40
Lp-Ado  MRS1523 396 9 390 11 39alues were expressed as mean  SEM. p  0.05 versus baseline.
Lp-Ado  PEGylated liposomal adenosine; PEG  polyethylene glycol; Vehicle  PEGylated liposomesation of the in vivo pharmacodynamics of PEGylated
iposomal adenosine is needed.
An intravenous infusion of PEGylated liposomal adeno-
ine at the maximum dose that did not disturb hemody-
amic parameters for 10 min before reperfusion reduced MI
ize in a dose-dependent manner, and this improvement was
locked by 8-SPT, a nonselective adenosine receptor antago-
ist. These findings suggest that adenosine released from
iposomes acts via an adenosine receptor-dependent path-
ay. One possible mechanism by which PEGylated lipo-
n
210 (min)
 of infarct size
1. Control (n=10)
2. Vehicle (n=8)
3. Free Ado (n=6)
4. Lp Ado 50 µg/kg/min (n=6)
5. Lp Ado 150 µg/kg/min (n=6)
6. Lp Ado 450 µg/kg/min (n=8)
*
on Myocardial Infarct Size
rct size measurement. (B) Myocardial infarct size. Values are expressed as
Lp-Ado  PEGylated liposomal adenosine; Vehicle  PEGylated liposomes.
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denosine with minimum effects on hemodynamic param-
ters is the enhanced accumulation of PEGylated liposomal
denosine in ischemic/reperfused myocardium, which could
ugment various beneficial actions such as preventing cal-
ium overload in the myocardium (5). The prolonged
ersistence of PEGylated liposomal adenosine would also
ncrease its beneficial effect on ischemic/reperfused myocar-
ium. Although continuous high-dose, long-term infusion of
ree adenosine was reported to reduce infarct size in rats
16), the present study did not confirm such a cardioprotective
ffect, probably because the total dose of free adenosine that
e used was not high enough.
We found that myocardial infarct size in the group that
eceived PEGylated liposomal adenosine with the antago-
ist of adenosine A1, A2a, A2b, or A3 subtype receptor was
o different from the control group, indicating that every
denosine subtype receptor could possibly play a role in
ediating cardioprotection by liposomal adenosine and that
t was difficult to identify one particular subtype in the
resent study. Numerous studies reported that A1, A2a, A2b,
nd A3 receptors have been involved in cardioprotection
gainst ischemia/reperfusion injury, and it remains contro-
ersial which adenosine subtype receptor is most responsible
or cardioprotection (17–20). Furthermore, because the
denosine receptor antagonists used in the present study had
ome nonspecific effects, future investigation will be needed
o examine the precise role of each adenosine receptor
Figure 6 Effects of Adenosine Receptor Antagonists on Myoca
(A) Protocol showing the timing of infusion of PEGylated liposomal adenosine and
are expressed as the mean  SEM (error bars). *p  0.05 versus the control gro
tions as in Figure 5.ubtype using genetically engineered mice.Because liposomal adenosine infused during reperfusion
ould reduce MI size, this agent could be a candidate for the
djunctive therapy of patients with acute MI. Importantly,
denosine is currently used for the diagnosis of ischemic
eart disease and PEGylated liposomes are used to deliver
nticancer agents (21). Thus, it should not be difficult to
ntroduce PEGylated liposomal adenosine into clinical
ractice. Finally, PEGylated liposomes may provide a useful
rug delivery system for targeting ischemic/reperfused myo-
ardium with other agents.
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